Brokers Set Expectations for ACRS FY2029 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of Aclaris Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the biotechnology company will earn ($1.02) per share for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.86) per share.

ACRS has been the topic of a number of other reports. Jefferies Financial Group upgraded shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and boosted their target price for the stock from $2.00 to $7.00 in a report on Tuesday, November 19th. HC Wainwright upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Monday, December 23rd. BTIG Research upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 target price for the company in a research note on Tuesday, November 19th. StockNews.com downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. Finally, Piper Sandler raised Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $3.00 to $13.00 in a research report on Monday, November 18th. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $11.00.

Aclaris Therapeutics Stock Down 5.4 %

NASDAQ:ACRS opened at $2.43 on Thursday. The firm has a market capitalization of $173.58 million, a price-to-earnings ratio of -4.67 and a beta of 0.50. Aclaris Therapeutics has a twelve month low of $0.95 and a twelve month high of $5.17. The stock’s 50 day moving average price is $2.88 and its two-hundred day moving average price is $2.05.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The company had revenue of $4.35 million for the quarter, compared to analyst estimates of $8.31 million. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%.

Insider Buying and Selling at Aclaris Therapeutics

In other news, Director Anand Mehra acquired 666,666 shares of Aclaris Therapeutics stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $2.25 per share, for a total transaction of $1,499,998.50. Following the completion of the acquisition, the director now directly owns 710,030 shares in the company, valued at approximately $1,597,567.50. The trade was a 1,537.37 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 6.40% of the company’s stock.

Institutional Trading of Aclaris Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. acquired a new position in Aclaris Therapeutics in the 4th quarter valued at $82,000. Assenagon Asset Management S.A. bought a new stake in shares of Aclaris Therapeutics in the third quarter valued at about $214,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Aclaris Therapeutics by 187.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock valued at $382,000 after acquiring an additional 216,826 shares in the last quarter. Raymond James Financial Inc. bought a new position in Aclaris Therapeutics during the fourth quarter worth about $383,000. Finally, Geode Capital Management LLC raised its stake in Aclaris Therapeutics by 9.3% in the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock worth $974,000 after purchasing an additional 72,309 shares in the last quarter. 98.34% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.